TickerFacts.

Viridian Therapeutics, Inc. (VRDN): Cost of Revenue

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2014-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

Older than the company's other figures. The latest Cost of Revenue is for the year ended 2016-12-31, while the company's latest annual report covers the year ended 2025-12-31. Its later filings do not report this line under the concept TickerFacts maps.

$2.55M
Year ended 2016-12-31
$3.37M2013-12-31: $2.78M2014-12-31: $3.37M2015-12-31: $2.47M2016-12-31: $2.55M$2.55M
2013-12-31 Cost of Revenue (USD) 2016-12-31
Period endedCost of RevenueChange YoYSource filing
2016-12-31$2.55M+3.1%2017-03-24, From 2016-01-01
2015-12-31$2.47M-26.6%2017-03-24, From 2015-01-01
2014-12-31$3.37Mn/c2016-03-21, From 2014-01-01
2013-12-31$2.78Mn/a2015-03-27, From 2013-01-01